Biotechnology News and Research

RSS

Amphibian skin secretions can reveal amazing medicinal properties

Frogs place in culture ranges from the wise, to the prince in disguise. But it's the idea that a frog can produce life-saving medicine that's currently the subject of an international research project involving Professor Chris Shaw and colleagues at Queen's University Belfast, in Northern Ireland. They have discovered proteins in frog skins that could be used to treat cancer, diabetes, strokes and transplant patients by regulating the growth of blood vessels.

17 Aug 2011

Patient recruitment complete in Kuros' KUR-023 dural sealant European clinical trial

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has completed patient recruitment in a clinical trial investigating the safety and efficacy of KUR-023, its novel dural sealant product candidate.

17 Aug 2011

GE Healthcare announces acquisition of PAA Laboratories

GE Healthcare, a unit of General Electric Company, today announced it has reached an agreement to acquire PAA Laboratories, a developer and supplier of cell culture media for biomedical research and the fast-growing biopharmaceutical and vaccine manufacturing industry.

17 Aug 2011

HSS, pSivida enter orthopedic evaluation agreement

Drug delivery company pSivida Corp. today announced it has entered into an evaluation agreement with Hospital for Special Surgery (HSS), a world leader in orthopedics, rheumatology and rehabilitation, to investigate pSivida's drug delivery technologies in orthopedics.

17 Aug 2011

Pfizer, QIAGEN partner to develop diagnostic-therapeutic combination for NSCLC

QIAGEN today announced it has entered into a partnership with Pfizer Inc. for the development of a companion molecular diagnostic test for use with an investigational Pfizer compound in global clinical development for treatment of non-small cell lung cancer.

From QIAGEN Manchester Limited 16 Aug 2011

Akela total consolidated revenues increase to $7.3M for six months ended June 30, 2011

Akela Pharma, Inc. and PharmaForm, a leading specialty contract service provider in the area of pharmaceutical dosage form development and manufacturing, today announced its financial results for the three and six months and year ended June 30, 2011.

16 Aug 2011

Enrollment commences in RegeneRx RGN-259 Phase 2 trial for dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. has announced that the first patients have been enrolled and randomized to receive RGN-259 or placebo in its 72-patient, Phase 2 clinical trial in patients with dry eye syndrome.

16 Aug 2011

Increase in public awareness leads to lower obesity in children

Increasing public awareness of the childhood obesity epidemic may be contributing to evidence of overall reductions in body mass index (BMI), a measure of obesity in children, according to the results of a nationwide study presented in Childhood Obesity, a peer-reviewed journal published by Mary Ann Liebert, Inc.

12 Aug 2011

Kineta's next generation antiviral program receives $2.8 million NIH SBIR grant

Kineta, Inc. announced today its next generation antiviral program has received a 2.8 million dollar grant from the National Institute of Allergy and Infectious Disease, a part of the National Institutes of Health (NIH). Awarded under the Small Business Innovation Research (SBIR) program, the prestigious phase two grant will provide on-going support for Kineta's work on a new class of antiviral drugs targeting an array of global, deadly viruses.

12 Aug 2011

Echo net loss for first half 2011 increases to $6.5 million

Echo Therapeutics, Inc., a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude SkinPrep System for transdermal drug delivery, today announced results for the period ended June 30, 2011.

12 Aug 2011

Advaxis completes ADXS-PSA prostate cancer construct pre-IND meeting with the FDA

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has completed a pre-IND (Investigational New Drug) meeting with the FDA on August 10 to discuss the development plan for ADXS-PSA, a construct for the treatment of prostate cancer.

12 Aug 2011

ShangPharma approves share repurchase program

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its Board of Directors has approved a share repurchase program.

12 Aug 2011

Medical College of Wisconsin to establish National Center for Systems Biology

The Medical College of Wisconsin has received a five-year, $13 million grant to establish a National Center for Systems Biology.

12 Aug 2011

New model for amyotrophic lateral sclerosis

By isolating cells from patients' spinal tissue within a few days after death, researchers funded by the National Institutes of Health have developed a new model of the paralyzing disease amyotrophic lateral sclerosis.

12 Aug 2011

ShangPharma achieves initial milestones for two oncology projects

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it has achieved the initial milestones for two multi-staged projects in its biologics division, which portends strong growth for this segment in 2011.

11 Aug 2011

Pacira second quarter total revenues increase to $3.6 million

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the second quarter ended June 30, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL, and updated its 2011 financial guidance.

11 Aug 2011